DXB is a small molecule company, 1AD is a biologicals company. They're looking at different indications. They both have different targets. So there's no objective comparison to be made as the regulatory provisions are vastly different. DMX has an 'identification' technology but AD1 has a drug discovery and optimisation platform. As soon as the platform is de-risked the platform is a better investment than the 'identification technology in my view as it has the capability to spit out lead or promising mAb-like candidates and optimise them quite quickly. No small molecule company can say that. DYOR - AHMHO
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.338M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 26482277 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 13641920 | 16 |
View Market Depth
| Last trade - 10.59am 07/08/2025 (20 minute delay) ? |
| 1AD (ASX) Chart |
Day chart unavailable